EX-99.1 3 dex991.htm PRESS RELEASE OF MOORE MEDICAL CORP., DATED APRIL 25,2003 PRESS RELEASE OF MOORE MEDICAL CORP., DATED APRIL 25,2003

 

[MOORE MEDICAL LOGO]

News

 

Exhibit 99.1

Contacts:

   

John M. Zinzarella, CPA

Moore Medical Corp.

Vice President of Finance, Treasurer and

Chief Financial Officer

860-826-3655

jzinzarella@mooremedical.com

 

Allyne Mills

Rosica Mulhern Strategic Public Relations

201-843-5600

allyne@rosica.com

 

FOR IMMEDIATE RELEASE

 

MOORE MEDICAL ANNOUNCES FIRST QUARTER 2003 OPERATING RESULTS

 

NEW BRITAIN, CT – April 25, 2003 – Moore Medical Corp. (AMEX:MMD), a leading multi-channel specialty marketer and distributor of medical, surgical and pharmaceutical products to health care professionals in non-hospital settings, today announced a first quarter 2003 net loss of ($0.05) per diluted share, versus income of $0.06 per diluted share in the first quarter of 2002.

 

The Company’s first quarter 2003 loss of ($0.05) per diluted share on a net loss of ($0.2) million compared to income of $0.06 per diluted share on net income of $0.2 million in the comparable period one year ago. First quarter 2003 net sales were $33.6 million, an increase of 3.7% from $32.4 million in the previous year’s first quarter. Net sales growth fell short of the Company’s expectations for the quarter primarily due to a slower than expected return on the fourth quarter 2002 investment in the Company’s primary care sales force and was further impacted by severe weather conditions in the month of February.

 

First quarter gross profit as a percentage of net sales decreased by 0.6%, to 27.1% from 27.7% in the same quarter last year, as a result of continuing external price pressures in certain markets and aggressive pricing associated with gaining entry into competitively held new accounts. These effects offset the benefits from supply chain efficiencies that contributed significantly to our profits in fiscal 2002. Sales and marketing expenses increased $0.3 million, or 11.8% over last year’s first quarter, reflecting increased expenses related to the Company’s expansion and training of field sales staff in the fourth quarter 2002. General and administrative expenses increased $0.3 million, or 4.9%, to $6.4 million in the first quarter of 2003 from $6.1 million in last year’s first quarter, due to higher costs related to net periodic pension expense, professional services fees and property and casualty insurance expense.

 

“During the fourth quarter of 2002, Moore Medical expanded its field sales force and product portfolio to ensure long-term growth,” said Linda M. Autore, president and chief executive officer of

 

1


Moore Medical Corp. “The sales levels achieved for the first quarter fell short of expectations and did not generate sufficient income to offset the investment’s incremental costs. We are firmly committed to our growth strategy and continue to believe our investments will result in improvement in revenue and profitability during the remainder of fiscal 2003.”

 

About Moore Medical

 

Moore Medical is an Internet-enabled multi-channel marketer and distributor of medical, surgical and pharmaceutical products to approximately 100,000 health care practices and facilities in non-hospital settings nationwide, including: physicians; emergency medical technicians; schools; correctional institutions; municipalities; occupational/industrial health doctors and nurses; and other specialty practice communities. Moore Medical also serves the medical/surgical supply needs of over 28 customer community affiliates. The Company markets and serves its customers through direct mail, industry-specialized telephone support staff, field sales representatives, and the Internet. Its direct marketing and distribution business has been in operation for 55 years. More information about the Company can be found at www.mooremedical.com.

 

“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. This press release contains statements about future events and expectations that constitute forward-looking statements under the federal securities laws. These statements are characterized by words such as “believe,” “may,” “will,” “could,” “should,” “would,” “anticipate,” “estimate,” “expect,” “intent,” “project,” “objective,” “seek,” “strive,” “might,” “seeks,” “likely result,” “build,” “grow,” “plan,” “goal,” “expand,” “position,” or similar words. Forward-looking statements involve risks and uncertainties (including factors outside our control) that may cause our actual results, performance or financial condition to differ materially from any future results implied by such forward-looking statements. Factors that could contribute to these differences include, but are not limited to: the inability to generate adequate revenues and income from our strategy to transform the Company to a multi-channel e-commerce enabled business; changes in demand for or supply of our products; online security breaches; disruptions in or cost increases for third-party services or systems; intense competition in health care product distribution; government regulation of drug and medical device distribution, the Internet and health care products and services; and changes in insurance coverage of health care products and services. Further information regarding factors that could affect our results and the statements made herein are included in our filings with the Securities and Exchange Commission.

 

Financial Statements to Follow

 

2


MOORE MEDICAL CORP. & SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED

 

Unaudited

                   

(Amounts in thousands, except per share data)


    

March 29, 2003


      

March 30, 2002


Net sales

    

$

33,613

 

    

$

32,437

Cost of products sold

    

 

24,519

 

    

 

23,441

      


    

Gross profit

    

 

9,094

 

    

 

8,996

Sales and marketing expenses

    

 

2,870

 

    

 

2,566

General and administrative expenses

    

 

6,437

 

    

 

6,080

      


    

Operating (loss) income

    

 

(213

)

    

 

350

Interest expense, net

    

 

43

 

    

 

47

      


    

(Loss) income before income taxes

    

 

(256

)

    

 

303

Income tax (benefit) provision

    

 

(92

)

    

 

108

      


    

Net (loss) income

    

$

(164

)

    

$

195

      


    

Basic net (loss) income per share

    

$

(0.05

)

    

$

0.06

Diluted net (loss) income per share

    

$

(0.05

)

    

$

0.06

Basic common shares outstanding*

    

 

3,190

 

    

 

3,154

Diluted common shares outstanding*

    

 

3,190

 

    

 

3,177


*weighted average

 

3


MOORE MEDICAL CORP. & SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

 

(Amounts in thousands, except par value)


  

March 29, 2003


    

December 28, 2002


ASSETS

  

 

(Unaudited)

        

Current Assets

               

Cash and cash equivalents

  

$

100

    

$

100

Accounts receivable, less allowances of $1,371 and $1,249, respectively

  

 

18,602

    

 

17,187

Inventories

  

 

10,958

    

 

11,230

Prepaid expenses and other current assets

  

 

1,635

    

 

1,216

Deferred income taxes

  

 

1,871

    

 

1,871

    

    

Total Current Assets

  

 

33,166

    

 

31,604

    

    

Noncurrent Assets

               

Property, plant and equipment, net

  

 

6,199

    

 

6,254

Other assets

  

 

2,202

    

 

2,137

    

    

Total Noncurrent Assets

  

 

8,401

    

 

8,391

    

    

    

$

41,567

    

$

39,995

    

    

LIABILITIES AND SHAREHOLDERS' EQUITY

               

Current Liabilities

               

Accounts payable

  

$

8,395

    

$

5,794

Amounts due to customers

  

 

2,126

    

 

2,342

Accrued expenses

  

 

1,678

    

 

1,723

Cash overdraft

  

 

1,335

    

 

1,632

Current portion long-term debt

  

 

3,799

    

 

—  

    

    

Total Current Liabilities

  

 

17,333

    

 

11,491

    

    

Deferred Income Taxes

  

 

855

    

 

855

Accrued Pension

  

 

408

    

 

233

Long-Term Debt

  

 

—  

    

 

4,281

Total Shareholders’ Equity

  

 

22,971

    

 

23,135

    

    

    

$

41,567

    

$

39,995

    

    

 

4